A PYMNTS Company

Sweden/Italy: $3.1B deal propels pharmaceutical consolidation

By  |  July 31, 2014

The world’s pharmaceutical industry continued its trend of consolidation Thursday as Sweden-based drug company Meda announced plans to acquire Italy’s Rottapharm for $3.1 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reports say the takeover marks the largest merger ever struck in Media’s history.

    The pharmaceutical giant had earlier said that it prefers “to eat and not be eaten” in a global market that has seen a wave of M&A activity in recent months. According to reports, Meda has turned down a takeover offer by Mylan, based in the US.

    Some industry experts had hoped Mylan would up its bid for the deal, but those hopes were dashed when Mylan acquired a portfolio from rival Abbott earlier last month.

    Meda and Rottapharm expect to finalize the deal in the fourth quarter.

    Full content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.